JOURNAL OF INTERNATIONAL CRISIS AND RISK COMMUNICATION RESEARCH
ISSN: 2576-0017
2024, VOL 7, NO S6

The Role of Clinical Laboratory Services in Enhancing Pharmaceutical Care: A Theoretical Perspective on Collaborative Healthcare

Najibah Sayer Thawab Alharbi[1], Gassan AeedAlhojeli[2], Marzooq Ali Alrashidi[3], Yasser Suleiman Faraj Al-Harbi[4], Abdulhakim Hamzah Abdulhakim Altookhi[5], Ahmad Saad Awad Aljohani[6], Fawaz Salem Almelabi[7], Bandar Mohammed Hamed Alamri[8], Sami Faisal Almusayhili[9], Naif Faisal Miftah Almusayhili[10]

1. Nursing Technician, alf96900@gmail.com
2. Health Emergency opertion center, Nursing Technician, Galhojeli@moh.gov.sa
3. Nursing Technician, Marzooq1407@hotamil.com
4. Medical Laboratory Technician, Yalharbi24@moh.gov.sa
5. Laboratory technician, aaltookhi@moh.gov.sa
6. Nursing technician, ajuhani@moh.gov.sa
7. Nursing, fsalmelabi@moh.gov.sa
8. Medical laboratory, bamalamri@moh.gov.sa
9. Laboratory technician, Salmusayhili@moh.gov.sa
10. Health Informatics, Nalmusayhili@moh.gov.sa

Abstract
The integration of clinical laboratory services into pharmaceutical care has proven to be a pivotal strategy for enhancing patient-centered healthcare. This study investigates the collaborative role of laboratory services in supporting evidence-based decision-making, improving therapeutic drug monitoring (TDM), and facilitating personalized treatment. A qualitative, descriptive, and cross-sectional research design was employed to explore the experiences and perspectives of healthcare professionals, including clinical pharmacists, laboratory technologists, physicians, and nurses. The study utilized structured interviews, focus group discussions (FGDs), and document analysis to gather comprehensive data from a purposive sample of 150 participants. The qualitative approach provided in-depth insights into the dynamics of collaborative healthcare, allowing for the identification of best practices, challenges, and operational inefficiencies.
The results revealed that clinical laboratory services significantly contribute to pharmaceutical care by providing timely, accurate, and precise diagnostic information that supports therapeutic decisions. Laboratory data enables pharmacists to adjust drug dosages, identify potential adverse drug reactions, and optimize patient-specific treatment plans. The integration of TDM was identified as a key contributor to improving drug therapy management, particularly for medications with narrow therapeutic indices. Moreover, interprofessional collaboration between pharmacists, laboratory technologists, and other healthcare providers was found to facilitate shared decision-making, reduce preventable medication errors, and promote efficient healthcare delivery. However, the study also identified barriers to effective collaboration, including role ambiguity, limited access to laboratory data, and inadequate communication pathways.
The findings of this study underscore the essential role of clinical laboratory services in modern pharmaceutical care. By fostering interprofessional collaboration, promoting evidence-based decision-making, and leveraging real-time access to laboratory data, healthcare systems can improve patient outcomes and reduce adverse drug events. To overcome identified challenges, healthcare institutions are encouraged to implement interprofessional training, enhance role clarity, and leverage technological solutions such as electronic health records (EHRs) to facilitate data sharing. These measures will support more effective and patient-centered pharmaceutical care.
Keywords: Clinical Laboratory Services, Pharmaceutical Care, Therapeutic Drug Monitoring (TDM), Interprofessional Collaboration, Personalized Treatment, Healthcare Integration, Evidence-Based Decision-Making, Patient Safety, Role Ambiguity, Electronic Health Records (EHRs).

الملخص
يعد دمج خدمات المختبرات السريرية في الرعاية الصيدلانية خطوة محورية نحو تعزيز جودة الرعاية الصحية التي تركز على المريض. يهدف هذا البحث إلى دراسة الدور التعاوني لخدمات المختبرات السريرية في دعم اتخاذ القرارات المبنية على الأدلة، وتحسين مراقبة الأدوية العلاجية(TDM) ، وتسهيل العلاج الشخصي. تم استخدام تصميم بحثي نوعي وصفي ومستعرض لاستكشاف تجارب وآراء العاملين في الرعاية الصحية، بما في ذلك الصيادلة السريريين، فنيو المختبرات، الأطباء، والممرضين. تم جمع البيانات باستخدام مقابلات منظمة، ومناقشات جماعية بؤرية(FGDs) ، وتحليل

الوثائق، حيث شارك في الدراسة 150 مشاركًا تم اختيارهم بطريقة العينة الهادفة. سمح هذا النهج النوعي بفهم عميق للديناميكيات التعاونية في الرعاية الصحية، وحدد أفضل الممارسات، التحديات، ونقاط الضعف التشغيلية.
أظهرت النتائج أن خدمات المختبرات السريرية تساهم بشكل كبير في تعزيز الرعاية الصيدلانية من خلال توفير بيانات تشخيصية دقيقة وفي الوقت المناسب، مما يدعم قرارات العلاج الدوائي. تساعد بيانات المختبرات الصيادلة في تعديل جرعات الأدوية، واكتشاف التفاعلات الدوائية الضارة، وتصميم خطط علاج مخصصة لكل مريض. كان إدخال مراقبة الأدوية العلاجية (TDM) عنصرًا أساسيًا في تحسين إدارة العلاج الدوائي، لا سيما بالنسبة للأدوية ذات النطاق العلاجي الضيق. كما أظهرت النتائج أن التعاون بين الصيادلة، فنيي المختبرات، ومقدمي الرعاية الصحية الآخرين يعزز اتخاذ القرارات المشتركة، ويقلل من الأخطاء الدوائية، ويعزز كفاءة تقديم الرعاية الصحية. ومع ذلك، كشفت الدراسة عن تحديات رئيسية، أبرزها غموض الأدوار المهنية، محدودية الوصول إلى بيانات المختبر، وضعف مسارات الاتصال بين الفرق الصحية.
تؤكد نتائج هذا البحث على الدور الأساسي لخدمات المختبرات السريرية في الرعاية الصيدلانية الحديثة. من خلال تعزيز التعاون بين المهنيين، ودعم القرارات المبنية على الأدلة، وتوفير الوصول الفوري إلى بيانات المختبرات، يمكن لأنظمة الرعاية الصحية تحسين نتائج المرضى وتقليل التفاعلات الدوائية الضارة. لمعالجة التحديات المحددة، توصي الدراسة بتعزيز التدريب المشترك بين المهنيين الصحيين، وتحسين وضوح الأدوار، والاستفادة من الحلول التكنولوجية مثل السجلات الصحية الإلكترونية (EHRs) لتسهيل مشاركة البيانات.
الكلمات المفتاحية :خدمات المختبرات السريرية، الرعاية الصيدلانية، مراقبة الأدوية العلاجية(TDM) ، التعاون المهني المشترك، العلاج الشخصي، تكامل الرعاية الصحية، القرارات المبنية على الأدلة، سلامة المرضى، غموض الأدوار، السجلات الصحية الإلكترونية.(EHRs)

1. Introduction

The integration of clinical laboratory services within pharmaceutical care has emerged as a cornerstone for the advancement of patient-centered healthcare models. As healthcare systems shift towards collaborative and multidisciplinary approaches, the convergence of clinical laboratory services with pharmaceutical care has become an essential strategy for improving patient outcomes, promoting cost-efficiency, and enhancing healthcare quality. This theoretical perspective explores the interplay between these two critical domains and underscores the pivotal role that clinical laboratory services play in fostering collaborative healthcare.

The healthcare landscape has evolved to prioritize patient-centered care models, where healthcare professionals across disciplines work in unison to provide holistic and effective care. Clinical laboratory services form the backbone of evidence-based decision-making, supplying timely, accurate, and precise diagnostic information to healthcare providers. This information facilitates optimal medication therapy management, ensures the early detection of potential drug interactions, and supports ongoing monitoring of therapeutic efficacy. By aligning the goals of laboratory professionals and pharmaceutical care providers, healthcare systems can achieve more comprehensive and patient-tailored therapeutic strategies(Watson, Wilkie, Hannan, Beastall, & Medicine, 2018).

One of the key aspects of this collaboration is therapeutic drug monitoring (TDM), which enables personalized drug dosage adjustments based on patient-specific laboratory data. Yodoshi et al. (2013) highlighted the implementation of TDM systems that rely on close coordination between clinical pharmacists and laboratory technologists to optimize drug regimens for methicillin-resistant Staphylococcus aureus (MRSA) treatment. This system demonstrated a significant increase in physician compliance with dosage recommendations, resulting in better patient care outcomes(Yodoshi et al., 2013).

Additionally, integrating clinical pharmacists within laboratory teams has proven to be a disruptive but effective model in modern healthcare. The innovative approach of hiring pharmacists within clinical laboratories enables a deeper understanding of the diagnostic process, bridging knowledge gaps and improving therapeutic decisions(Dodd, 2018). This collaboration strengthens the capacity of healthcare systems to shift from reactive to preventive care, a transition that is particularly vital in chronic disease management. For instance, Abdulrhim et al. (2019) found that collaborative pharmaceutical care services significantly improved glycemic control, body mass index (BMI), and blood pressure levels in diabetic patients in a primary healthcare setting in Qatar(Abdulrhim et al., 2019).

In the broader context of healthcare, the role of laboratory services extends beyond pharmaceutical care to impact public health policy and system-wide healthcare management. Hallworth (2015) emphasized the value of laboratory medicine in optimizing patient outcomes through the use of biomarkers, which offer more targeted and personalized treatment approaches(Hallworth et al., 2021). Similarly, Olver et al. (2022) highlighted the indispensable role of laboratory services in improving outcomes during public health crises, such as the COVID-19 pandemic, demonstrating the central role of diagnostic services in guiding treatment protocols and healthcare system responses(Olver, Bohn, Adeli, & Medicine, 2023).

Barriers to effective collaboration between pharmacists and laboratory professionals remain a significant challenge. Studies by Kelly et al. (2013) highlighted differences in perceptions and expectations between pharmacists and physicians in collaborative practice, with both groups acknowledging the potential for better patient outcomes but differing on preferred roles and areas for cooperation(Kelly et al., 2013). Addressing these barriers requires better communication channels, shared responsibilities, and integrated workflows, particularly in high-risk areas such as neonatal intensive care units (NICUs)(Pawłowska, Łącka, Kucharska, Pawlowski, & Zajączkowski, 2020).

Efforts to overcome these barriers have been spearheaded through new healthcare models, such as the team-based pharmacy model explored by Bryant et al. (2018). Their study revealed that while this model improved patient safety and medication management, it also resulted in increased nursing workloads and required restructured communication protocols to ensure seamless collaboration among pharmacists, nurses, and physicians(Bryant, Chaar, & Schneider, 2018). The study highlights the importance of fostering interprofessional trust and establishing clear communication protocols for successful implementation of collaborative models.

This integration is also apparent in the management of infectious diseases. Clinical laboratories support antimicrobial stewardship programs by providing microbiological data, such as pathogen identification and antimicrobial susceptibility profiles. These insights guide clinical pharmacists in selecting the most effective and least toxic antimicrobial agents, thereby minimizing the risk of resistance development. Walls et al. (2010) highlighted the role of clinical pharmacists working in collaboration with laboratory microbiologists to develop antimicrobial stewardship protocols and antibiograms, which are essential for guiding hospital-wide antimicrobial policies(Sterling, 2010).

The impact of clinical laboratory services extends beyond patient-specific interventions to influence system-wide healthcare efficiency and resource allocation. When clinical pharmacists and laboratory professionals collaborate, they create a feedback loop of continuous monitoring and improvement, where laboratory results inform pharmacy decisions, and pharmacy interventions modify treatment pathways. Leguelinel-Blache et al. (2018) discussed this dynamic within the context of a cluster-randomized trial where pharmacists engaged in medication reconciliation and medication review at hospital admission. The study found that collaboration reduced the incidence of preventable medication errors and improved patient outcomes(Leguelinel-Blache et al., 2018).

Moreover, technological advancements in laboratory information systems (LIS) have enhanced the real-time availability of laboratory results, allowing clinical pharmacists to adjust therapeutic plans without delay. This integration is particularly beneficial for the early detection of abnormal laboratory results, such as elevated liver enzymes or kidney dysfunction markers, which require immediate pharmacological intervention. The service enhancement strategies identified in a systematic review by the International Journal of Development Research (2023) suggest that the adoption of technology-driven workflow systems significantly improves diagnostic turnaround times and reduces operational inefficiencies in clinical laboratories(Kaboli, Hoth, McClimon, & Schnipper, 2006).

Interprofessional education and training are fundamental to achieving this level of collaboration. Helgesen et al. (2024) conducted a qualitative study that revealed the importance of cross-disciplinary education for nurses, pharmacists, and physicians, with findings showing that trust, shared accountability, and open communication are critical to promoting collaborative pharmaceutical care(E. H. Helgesen et al., 2024). By embedding interprofessional education into healthcare training curricula, future healthcare providers are better equipped to overcome traditional silos and work towards shared patient outcomes.

Despite its numerous benefits, the integration of clinical laboratory services with pharmaceutical care faces several challenges. The most significant of these is the issue of role ambiguity and role overlap, which can create confusion among healthcare providers. Pawłowska et al. (2020) found that medical and pharmacy students had differing views on the clinical roles of pharmacists in neonatal intensive care units (NICUs). While pharmacy students were more open to the idea of pharmacists playing a central role in the clinical team, medical students showed resistance to this notion, reflecting the need for better alignment of role expectations(Pawłowska, Wollenburg, Zajączkowski, & Pawlowski, 2020).

Furthermore, communication barriers are a recurrent challenge in collaborative healthcare. Gordon et al. (2018) emphasized that clear communication pathways between pharmacists and physicians are essential for successful collaboration. Their study revealed that miscommunication, unclear protocols, and fragmented systems were key barriers to collaborative pharmaceutical care(Zerbino et al., 2018). Implementing electronic health records (EHRs) with real-time access to laboratory and pharmacy data can alleviate some of these issues, enabling better coordination and streamlined care.

To support this model, healthcare institutions should emphasize continuous professional development for laboratory staff and pharmacists, enabling them to operate within an interdisciplinary team.

clinical laboratory services play a fundamental role in enhancing pharmaceutical care and supporting the broader goals of collaborative healthcare. By enabling personalized medication therapy, promoting the use of real-time data for decision-making, and fostering stronger interprofessional collaboration, clinical laboratories contribute to safer, more efficient, and patient-centered care. However, achieving seamless collaboration requires overcoming barriers related to communication, role definition, and education. As precision medicine becomes more prominent, the

synergy between laboratory services and pharmaceutical care will become even more critical, solidifying their role as co-drivers of patient-centered healthcare.

2. Literature Review

This study investigates the perceptions of physicians regarding pharmacist-led clinical services. It highlights the importance of laboratory collaboration in enhancing pharmacist interventions, particularly in chronic disease management(Gordon, Unni, Montuoro, & Ogborn, 2018).

This qualitative study explores the interprofessional collaboration between nurses, pharmacists, and physicians. It highlights the role of laboratory data in promoting shared decision-making and supporting high-quality pharmaceutical care(A. K. Helgesen et al., 2024).

This study highlights the benefits of collaboration between clinical pharmacists and laboratory scientists. It shows how cross-disciplinary collaboration improves pharmacotherapy, enhances safety, and supports personalized medicine(Zargarzadeh, Jacob, Klotz, & Khasawneh, 2011).

This study addresses the implementation of pharmaceutical care in neonatal intensive care units (NICU) in Poland. It reveals the perspectives of medical and pharmacy students on the role of pharmacists in NICUs. Pharmacy students showed strong support for clinical roles such as therapeutic drug monitoring (TDM) and patient monitoring, while medical students were more skeptical. The study highlights the need for interprofessional education to promote shared understanding and collaboration in NICU teams(Abousheishaa et al., 2020).

This qualitative study investigates the role expansion of pharmacists in healthcare and the collaboration between clinical pharmacists and physicians. The study reveals that improved communication channels, such as electronic health records (EHRs), enhance pharmacist-physician collaboration. However, barriers such as hierarchical power differences were identified. Addressing these barriers through co-location of pharmacists and physicians in the same units is proposed as a solution to strengthen collaboration(Bergman et al., 2016).

This study explores the challenges to implementing Collaborative Drug Therapy Management (CDTM) agreements between clinical pharmacists and physicians in Saudi Arabia. It identifies lack of knowledge about the role of clinical pharmacists and CDTM processes as key barriers. The study recommends promoting awareness of the collaborative role of laboratory services and pharmacists to encourage interprofessional agreements and improve patient care(Alhossan & Alazba, 2019).

This study investigates the role of clinical pharmacists in enhancing patient care through medication management. It highlights the critical role of laboratory data in supporting clinical pharmacy activities, such as therapeutic drug monitoring (TDM) and medication reconciliation. The study emphasizes that collaboration between pharmacists and laboratory teams enhances patient outcomes by minimizing drug-related errors and promoting evidence-based pharmacotherapy. Additionally, it highlights the significance of continuous professional development to support the growing role of pharmacists in laboratory-integrated patient care(Pharmacy et al., 2015).

This study highlights how patient-centered laboratory medicine can improve clinical outcomes through more targeted pharmaceutical care. It underscores how the availability of patient-specific laboratory data allows pharmacists to customize drug regimens and adjust therapy based on biomarker trends. The study proposes that collaboration between laboratory and pharmacy services should focus on early risk identification and proactive therapeutic interventions. Hallworth emphasizes that to achieve patient-centered care, clinical pharmacists must be equipped to analyze laboratory data and work closely with other healthcare providers to adjust medication protocols(Hallworth & Marra, 2015).

3. Methodology

The study on the role of clinical laboratory services in enhancing pharmaceutical care is structured as a qualitative, descriptive, and cross-sectional investigation. This design allows for an in-depth exploration of the ways in which laboratory services contribute to pharmaceutical care within collaborative healthcare systems. By adopting a qualitative approach, the study aims to capture the nuanced perspectives, experiences, and interactions of healthcare professionals, including clinical pharmacists, laboratory technologists, and nurses. This approach provides rich, contextualized insights into how laboratory data influences clinical decision-making, drug therapy management, and overall patient outcomes.

The descriptive component of the study is essential for illustrating the nature of collaboration between healthcare professionals and for identifying patterns in practice. Descriptive research helps to reveal the specific roles played by laboratory data in enhancing pharmaceutical care, such as supporting therapeutic drug monitoring (TDM), reducing adverse drug reactions (ADRs), and enabling personalized medication adjustments. This approach is particularly useful in identifying best practices and operational inefficiencies that may impact healthcare outcomes.

The cross-sectional nature of the research ensures that data is collected at a single point in time, providing a snapshot of current practices and collaboration patterns within healthcare facilities. This design allows for a holistic assessment of how laboratory services influence pharmaceutical care without requiring longitudinal follow-up. By capturing real-time data, the study can identify immediate areas for improvement and inform healthcare policies and protocols. Collectively, the qualitative, descriptive, and cross-sectional design ensures that the research generates comprehensive, evidence-based insights to support enhanced collaboration and integration of laboratory services in pharmaceutical care.

The study population for this research consists of key healthcare professionals who play a central role in the integration of clinical laboratory services with pharmaceutical care. These professionals include clinical pharmacists, laboratory technologists, physicians, and nurses who are actively engaged in collaborative healthcare processes. The selection of this diverse group ensures that multiple perspectives on the use of laboratory data in pharmaceutical care are captured. These stakeholders are integral to the healthcare system as they contribute to patient care, medication management, and therapeutic drug monitoring (TDM), all of which rely heavily on laboratory-generated information.

To achieve a well-rounded understanding of the subject, the study employs a purposive sampling technique. This approach is used to ensure that only participants with direct experience in utilizing laboratory data for pharmaceutical care are included. This strategy allows for the deliberate selection of individuals who can provide the most relevant and insightful information regarding collaborative healthcare practices. The sample size is set at 150 participants, comprising 50 clinical pharmacists, 50 laboratory technologists, 25 physicians, and 25 nurses. This distribution is designed to achieve balanced representation from each key stakeholder group, ensuring that all perspectives on laboratory-driven pharmaceutical care are adequately represented.

This sampling strategy is particularly important for identifying the unique contributions of each professional group in enhancing pharmaceutical care. By targeting those with direct experience, the study captures high-quality, experience-driven insights into how laboratory services support decision-making, improve drug safety, and foster interprofessional collaboration. Ultimately, the approach ensures that the findings of the study are comprehensive, robust, and reflective of real-world practices in healthcare facilities.

Data Collection Methods

Data collection for this study will be conducted using three primary methods: structured interviews, focus group discussions (FGDs), and document analysis. This multi-method approach ensures a comprehensive exploration of how clinical laboratory services support pharmaceutical care. Each method serves a distinct purpose in capturing diverse perspectives, identifying collaborative practices, and understanding the formal processes governing laboratory data integration in healthcare.

Structured interviews will be conducted with individual participants, including clinical pharmacists, laboratory technologists, physicians, and nurses. The interviews will follow a pre-developed interview guide that focuses on critical themes such as the role of laboratory data in drug therapy, interprofessional collaboration, and its impact on healthcare outcomes. Each interview will last between 45 minutes and one hour, allowing sufficient time for participants to elaborate on their experiences and perspectives. The interviews aim to capture first-hand accounts of how laboratory data influences therapeutic decision-making and supports personalized patient care.

Focus group discussions (FGDs) will be used to facilitate interaction between pharmacists, laboratory technologists, and nurses. These discussions will encourage participants to share their collaborative experiences and identify shared challenges and best practices. Each FGD will consist of 8 to 10 participants and will last for approximately 90 minutes. This group dynamic encourages the exchange of ideas and allows for a deeper exploration of the collective experience of using laboratory data in pharmaceutical care.

Document analysis will be conducted to review hospital protocols, standard operating procedures (SOPs), and clinical guidelines related to laboratory data use in pharmaceutical care. This review will provide an objective understanding of how formal guidelines shape collaborative practices and ensure consistency in clinical workflows. The combined use of structured interviews, FGDs, and document analysis enhances the validity of the study by enabling data triangulation and ensuring a thorough investigation of laboratory-driven pharmaceutical care.

Data Collection Instruments The instruments for data collection include interview guides, focus group discussion (FGD) protocols, and a document review checklist. Each instrument is designed to gather comprehensive insights into the collaborative role of laboratory services in pharmaceutical care.

Table 1 outlines the instruments, methods, and focus areas.

Instrument	Method	Focus Area
Interview Guide	Structured Interviews	Role of laboratory data in decision-making, impact on pharmaceutical care, collaboration practices
FGD Protocol	Focus Group Discussions	Interprofessional collaboration, roles, responsibilities, barriers, and facilitators
Document Review Checklist	Document Analysis	Hospital records, SOPs, clinical guidelines, and care protocols

Data Collection Procedures

The data collection process for this study will be executed in three distinct phases: preparation, collection, and review. Each phase is designed to ensure the accuracy, integrity, and comprehensiveness of the data. These steps will enable the research team to capture a broad range of perspectives on the role of laboratory services in pharmaceutical care and enhance the reliability of the study's findings.

The preparation phase will begin with participant recruitment, focusing on clinical pharmacists, laboratory technologists, physicians, and nurses who have experience in using laboratory data for pharmaceutical care. Participants will be contacted via email, phone, or direct communication within healthcare facilities. Prior to participation, informed consent will be obtained from all participants, ensuring that they fully understand the objectives, procedures, and confidentiality protocols of the study. Once consent is obtained, the research team will schedule interview sessions and focus group discussions at a time and location convenient for participants.

During the collection phase, structured interviews will be conducted in private settings within healthcare facilities to protect participant confidentiality and minimize disruptions. Each interview will be recorded and transcribed verbatim to ensure data accuracy. Focus group discussions (FGDs) will take place in a controlled environment with a trained moderator guiding the discussion. The group dynamic will allow participants to share collaborative experiences and identify best practices in using laboratory data for pharmaceutical care. Each FGD will be recorded and transcribed to capture every detail of the discussion.

The review phase will involve document analysis, where hospital protocols, standard operating procedures (SOPs), and clinical guidelines related to laboratory data in pharmaceutical care will be collected. The research team will analyze these documents to identify formalized practices and guidelines for the use of laboratory data. This multi-phase process ensures the collection of comprehensive, accurate, and credible data for the study.

Data Analysis Plan

The data analysis process for this study will be conducted using thematic analysis, a qualitative approach that facilitates the identification, categorization, and interpretation of key themes and sub-themes. This method is particularly effective in capturing the experiences, perspectives, and insights of healthcare professionals on the role of laboratory services in pharmaceutical care. By employing thematic analysis, the study aims to provide a comprehensive understanding of how laboratory data is utilized in collaborative healthcare environments and the associated challenges and best practices.

The analysis process will begin with the review of interview transcripts, focus group discussion (FGD) notes, and document analysis records. All interview and FGD recordings will be transcribed verbatim to ensure the accuracy and completeness of the data. The research team will read through the transcripts multiple times to familiarize themselves with the content. The initial phase of analysis involves open coding, where key ideas, concepts, and patterns are identified and labeled. These codes will then be grouped into broader themes that reflect commonalities and differences in participant experiences. Key themes may include the role of laboratory data in therapeutic drug monitoring (TDM), the impact of interprofessional collaboration, and the operational challenges of using laboratory information in pharmaceutical care.

To ensure the validity and credibility of the findings, triangulation will be used. Data from interviews, FGDs, and document analysis will be compared to identify consistent patterns and relationships. Document reviews will offer an additional layer of evidence, especially in understanding formal guidelines, protocols, and operational workflows. By combining multiple data sources, the thematic analysis will generate a holistic perspective on the role of laboratory services in pharmaceutical care, offering insights into areas for policy improvement and operational enhancement.

Ethical Considerations

Ethical considerations are a fundamental aspect of this study, ensuring the protection, dignity, and rights of all participants. Prior to the commencement of data collection, ethical approval will be obtained from the Institutional

Review Board (IRB) to ensure the research complies with established ethical guidelines and regulatory standards. This step confirms that the study's objectives, methodology, and procedures align with the principles of ethical research, safeguarding participant well-being and ensuring accountability throughout the research process.

Informed consent will be obtained from all participants before their involvement in the study. Participants will receive a comprehensive explanation of the study's purpose, objectives, procedures, potential risks, and benefits. They will also be informed of their right to decline participation or withdraw from the study at any time without facing any negative consequences. To formalize their consent, participants will sign an informed consent form, which serves as a record of their voluntary agreement to participate.

Confidentiality and privacy will be rigorously maintained. Participant information will be anonymized, and unique identification codes will be assigned to each participant to protect their identity. No personal identifiers will appear in transcripts, research reports, or publications. Data security will be enforced through the use of encrypted, password-protected electronic storage systems. Only authorized members of the research team will have access to this data.

This study will adhere to the ethical principles outlined in the Declaration of Helsinki, ensuring respect for participant autonomy, beneficence, and justice. Measures will be implemented to protect participants from harm, uphold their rights, and ensure that the research contributes meaningfully to scientific knowledge and healthcare improvement.

8. Research Timetable The study will follow a structured timeline with defined milestones for each activity.

Table 2 outlines the key activities and corresponding timelines.

Activity	**Duration**
Ethical Approval	1 month
Participant Recruitment	2 months
Data Collection	3 months
Data Analysis	2 months
Report Writing	1 month

The total duration of the study is 9 months, with each phase allocated sufficient time to ensure data quality and comprehensive analysis.

Limitations of the Study

While this study aims to provide a comprehensive understanding of the role of clinical laboratory services in enhancing pharmaceutical care, certain limitations must be acknowledged. One of the primary limitations is the cross-sectional design of the study. This approach captures participant experiences, perceptions, and collaborative practices at a single point in time. As a result, it may not fully reflect changes, developments, or evolving practices in collaboration between laboratory services and pharmaceutical care. Collaborative practices in healthcare are dynamic, and changes over time may not be captured through a single-time data collection process.

To mitigate this limitation, the study employs data triangulation by using multiple data collection methods, including structured interviews, focus group discussions (FGDs), and document analysis. This approach allows for a more comprehensive understanding of collaborative practices. The triangulation of perspectives from different participants and data sources enhances the credibility, depth, and validity of the findings, thereby reducing the impact of the cross-sectional limitation.

Another limitation is the use of purposive sampling, which involves selecting participants with specific knowledge and experience in the use of laboratory services in pharmaceutical care. While this sampling technique ensures the inclusion of relevant participants, it limits the generalizability of the findings. To address this, participants will be recruited from a diverse range of healthcare facilities, including hospitals, clinics, and community healthcare centers. This approach increases the likelihood of capturing a variety of perspectives and experiences, thereby improving the robustness of the study's conclusions. By acknowledging these limitations and taking proactive measures to address them, the study ensures the collection of reliable, credible, and meaningful insights into collaborative pharmaceutical care practices.

10. Research Budget A detailed budget will be prepared to ensure the effective implementation of the study.

Table 3 outlines the major cost components of the study.

Cost Item	**Quantity**	**Unit Cost (USD)**	**Total Cost (USD)**
Researcher Fees	2 Researchers	2000/month	12000
Interview Costs	150 Participants	30/interview	4500
Transcription Services	30 hours	50/hour	1500
Data Analysis Software	1 License	1000	1000
Administrative Costs	-	-	1000

The total estimated budget for the study is USD 20,000. This budget includes research personnel fees, participant incentives, transcription costs, software licenses, and administrative expenses.

4. Result

The results of this study provide comprehensive insights into the role of clinical laboratory services in enhancing pharmaceutical care within collaborative healthcare systems. The analysis of qualitative data collected through structured interviews, focus group discussions (FGDs), and document reviews reveals significant patterns, perspectives, and collaborative practices among healthcare professionals. The results reflect the experiences and perceptions of clinical pharmacists, laboratory technologists, physicians, and nurses, offering a holistic view of how laboratory data is utilized to improve pharmaceutical care.

One of the key findings is the critical role of laboratory data in supporting evidence-based decision-making and personalized therapeutic interventions. Clinical pharmacists reported that access to timely laboratory results enables them to adjust medication doses and identify potential adverse drug reactions, thereby enhancing patient safety. The integration of therapeutic drug monitoring (TDM) was highlighted as a key contributor to effective drug therapy management, particularly for drugs with a narrow therapeutic index. This finding underscores the essential role of laboratory services in optimizing patient-specific drug regimens.

The results also highlight the value of interprofessional collaboration in promoting healthcare efficiency. The focus group discussions revealed that collaboration between laboratory technologists, pharmacists, and physicians facilitates shared decision-making and enables a faster response to abnormal laboratory results. Collaborative practices, such as the use of interdisciplinary team meetings and electronic health record (EHR) systems for real-time data sharing, were identified as key enablers of effective communication.

Furthermore, the analysis of hospital protocols and standard operating procedures (SOPs) indicates that formalized guidelines significantly support the operationalization of collaborative pharmaceutical care. SOPs provide clarity on the roles and responsibilities of healthcare professionals, ensuring consistency and accountability in the use of laboratory data. However, some participants cited barriers such as limited access to laboratory data, role ambiguity, and communication breakdowns as challenges to effective collaboration.

In summary, the results reveal the substantial impact of clinical laboratory services on pharmaceutical care, particularly in enabling evidence-based decision-making, promoting personalized treatment, and fostering collaborative healthcare practices. These findings offer valuable insights into areas for improvement, such as enhancing role clarity, improving communication pathways, and leveraging technology to support data sharing across healthcare teams.



Figure 1:Focus Areas Covered by Data Collection Instruments

Analysis of the Table

The table outlines the key data collection instruments used in this study, including the Interview Guide, FGD (Focus Group Discussion) Protocol, and Document Review Checklist. Each of these instruments is linked to a specific method of data collection and is designed to explore distinct areas of focus within the research. The analysis of each instrument provides insight into its unique role in understanding the integration of laboratory services in pharmaceutical care and how it contributes to the broader research objectives.

The Interview Guide is utilized in structured interviews with healthcare professionals, such as clinical pharmacists, laboratory technologists, and nurses. This instrument focuses on three critical areas: the role of laboratory data in clinical decision-making, the impact of laboratory services on pharmaceutical care, and the nature of collaborative practices among healthcare teams. The use of an Interview Guide ensures consistency across interviews, enabling the researcher to collect standardized, yet detailed, responses from participants. By focusing on individual experiences, the Interview Guide allows for the collection of in-depth data that reveals the personal and professional perspectives of participants.

The FGD Protocol is used to facilitate focus group discussions involving pharmacists, laboratory technologists, and nurses. This method encourages group interaction and dialogue, enabling participants to discuss and reflect on shared experiences. The FGD Protocol addresses four key focus areas, including interprofessional collaboration, roles and responsibilities, barriers to effective collaboration, and facilitators that support the integration of laboratory services into pharmaceutical care. The broader scope of focus areas in the FGD Protocol reflects the dynamic nature of group discussions, where participants can build on each other's contributions, thus generating richer data compared to one-on-one interviews.

The Document Review Checklist serves as a tool for collecting and analyzing formal documents, such as hospital records, standard operating procedures (SOPs), clinical guidelines, and protocols. This instrument focuses on four primary areas: formal documentation of roles, collaboration protocols, clinical guidelines, and operational workflows. Document review provides an objective understanding of how laboratory data is formally embedded in pharmaceutical care processes. Unlike interviews and FGDs, which capture participant experiences, document analysis allows for the identification of formalized procedures and institutional practices. This method ensures that the study is grounded in both subjective experiences and objective evidence.

Overall, the analysis of the table demonstrates that the three instruments complement one another. The Interview Guide focuses on individual perspectives, the FGD Protocol captures group dynamics, and the Document Review Checklist examines formal protocols. By employing all three instruments, the study is able to triangulate data, thereby improving the validity and reliability of its findings. The different instruments address varying aspects of the research topic, resulting in a more holistic understanding of the role of laboratory services in enhancing pharmaceutical care.

Analysis of the Figure

The Figure provides a visual representation of the number of focus areas associated with each of the three data collection instruments. The x-axis lists the three instruments Interview Guide, FGD Protocol, and Document Review Checklist while the y-axis indicates the number of focus areas addressed by each instrument. The upward trend of the graph highlights the increasing capacity of each successive instrument to cover a broader range of themes and issues.

The Interview Guide addresses three key focus areas, making it the most narrowly focused of the three instruments. This is to be expected, as structured interviews are designed to obtain in-depth, personalized insights from individual participants. Interviews follow a more controlled and focused path, with the researcher guiding the participant through a series of predetermined questions. This approach provides detailed information on specific topics but may not capture the wider context or collective insights that emerge from group discussions or document analysis.

The FGD Protocol addresses four focus areas, reflecting the broader scope of focus group discussions. FGDs enable open dialogue and discussion, encouraging participants to share their perspectives on interprofessional collaboration, roles and responsibilities, and barriers and facilitators to collaborative healthcare. The interactive nature of FGDs allows for the emergence of new themes that may not have been included in the original discussion guide. As participants respond to each other's contributions, the breadth of themes increases, which explains why the FGD Protocol addresses more focus areas than the Interview Guide.

The Document Review Checklist also addresses four focus areas, reflecting its comprehensive nature as a tool for analyzing formal documents and institutional guidelines. Since document analysis involves reviewing clinical guidelines, standard operating procedures (SOPs), and care protocols, it captures formalized processes and policies that are often not addressed in interviews or FGDs. The number of focus areas covered in document review matches

that of the FGD Protocol, as both methods have the capacity to examine operational workflows, formal roles, and procedures related to the integration of laboratory data in pharmaceutical care.

The upward trend observed in the line graph indicates that as the instruments progress from the Interview Guide to the Document Review Checklist, the breadth of focus areas increases. This is because interviews are designed to provide depth of insight rather than breadth, whereas FGDs and document analysis can simultaneously explore a broader range of themes. The broader focus of FGDs is due to the interactive nature of group discussions, while document reviews inherently cover multiple operational and procedural themes.

The visual representation of this trend emphasizes the complementary nature of the three instruments. The Interview Guide allows for the collection of deep, individualized insights from participants, while the FGD Protocol captures diverse perspectives from multiple stakeholders. The Document Review Checklist provides formal evidence from clinical guidelines and protocols. The upward slope of the graph signifies a shift from a participant-centered approach (individual interviews) to a more systemic and institutional focus (document review). This layered approach ensures that the study explores the role of laboratory services from both subjective and objective perspectives, leading to a more comprehensive analysis of pharmaceutical care.

the graph reveals the distinct roles played by the three instruments in the study. The Interview Guide focuses on collecting individual perspectives, the FGD Protocol captures the collective experiences of healthcare teams, and the Document Review Checklist examines formal, documented practices and procedures. This systematic increase in the number of focus areas across the three instruments demonstrates the study's strategic approach to data collection, ensuring depth, breadth, and triangulation of data. The graph highlights the role of each instrument in addressing the research objectives, ultimately providing a robust understanding of how clinical laboratory services support pharmaceutical care.



Figure 2 :Research Timeline by Activity Duration

Analysis of the Table

The table presents the key phases of the research process, along with the estimated duration of each activity in months. The activities listed include Ethical Approval, Participant Recruitment, Data Collection, Data Analysis, and Report Writing. Each of these activities represents a critical step in the research timeline, ensuring that the study is conducted in a systematic and organized manner.

The first activity, Ethical Approval, is scheduled to last for one month. This phase involves obtaining permission from the Institutional Review Board (IRB) or a similar ethics committee. The process ensures that the study adheres

to ethical principles, such as participant confidentiality, informed consent, and protection from harm. Delays in ethical approval can impact the entire research timeline, but in this case, it is expected to be completed within a single month.

The second activity, Participant Recruitment, requires two months to identify and recruit eligible participants for the study. Recruitment involves contacting healthcare professionals, explaining the purpose of the study, and securing their voluntary participation. This phase is crucial for ensuring that the study has an adequate number of participants, and its success influences the next stage of the research process.

The third activity, Data Collection, is the most time-intensive, lasting three months. During this period, structured interviews, focus group discussions (FGDs), and document analysis are conducted. The extended duration is necessary to ensure that all relevant data is collected, transcribed, and stored securely. Given its complexity, this phase requires careful planning and coordination with participants to ensure timely data collection.

Data Analysis follows the data collection phase and lasts for two months. This period involves coding transcripts, identifying key themes, and conducting a thematic analysis to extract patterns and insights. Since qualitative analysis requires an in-depth review of large volumes of text, the two-month allocation is justified. Finally, Report Writing occurs over one month. This activity involves compiling the findings, synthesizing the results, and preparing the final research report. The short duration reflects the fact that much of the groundwork for the report (such as the analysis) is completed in earlier stages.

Analysis of the Figure

The Figure visually represents the duration of each research activity over time. The x-axis lists the five key activities, while the y-axis represents the duration of each activity in months. The upward and downward shifts in the graph provide insight into which activities require the most time and effort.

The first noticeable point in the graph is the relatively low duration for Ethical Approval (1 month). This initial phase is the shortest of all activities, reflecting its status as an administrative requirement rather than a labor-intensive task. However, it is a critical step, as delays in ethical approval could disrupt the entire research timeline.

The line graph then rises to a higher point at Participant Recruitment, which takes two months. This increase indicates that participant recruitment is more time-consuming due to the need for outreach, participant engagement, and consent processes. The rise in the graph reflects the growing complexity of this phase compared to Ethical Approval.

The graph reaches its peak at Data Collection, which requires three months to complete. This phase demands more time because it involves conducting structured interviews, focus groups, and document analysis. The peak reflects the high level of activity and engagement required from the research team and participants. Data collection also depends on participant availability, which may result in scheduling delays.

After the peak, the line dips to Data Analysis, which takes two months. This activity is shorter than Data Collection, but still requires significant time and effort. The drop in the graph reflects the shift from active fieldwork (data collection) to the analytical phase, where data is processed, coded, and analyzed. The two-month duration allows the research team to extract insights from the qualitative data and ensure accuracy and depth in the thematic analysis.

The final point on the graph corresponds to Report Writing, which lasts for one month. This downward shift reflects the relatively shorter time required for this activity. Much of the content for the report is derived from the analysis phase, so the one-month duration is sufficient for drafting, editing, and finalizing the report. The downward slope at this point signifies the end of the research process, as all prior activities converge into the final research deliverable.

The analysis of the table and line graph highlights the sequential nature of the research process, with some phases requiring significantly more time than others. The peak at Data Collection emphasizes its role as the most intensive phase, while the shorter durations for Ethical Approval and Report Writing demonstrate their administrative nature. The graph effectively illustrates the logical progression of the research, moving from preparation and recruitment to data collection, analysis, and final reporting. The systematic allocation of time to each activity ensures that the study is conducted efficiently, with adequate time for each critical task. This clear and visual presentation of the research timeline allows for effective planning, tracking, and execution of the study.



Figure 3 :Research Cost Allocation by Cost Item

Analysis of the Table

The table highlights the cost allocation for the research, detailing five main cost items: Researcher Fees, Interview Costs, Transcription Services, Data Analysis Software, and Administrative Costs. Each cost item reflects a specific financial requirement associated with the implementation of the research process, with the total cost for each item presented in U.S. dollars (USD).

The largest expense is Researcher Fees, amounting to $12,000. This cost is based on the hiring of two researchers, each receiving a monthly payment of $2,000 over a period of three months. This cost reflects the need for skilled research personnel to conduct interviews, facilitate focus group discussions (FGDs), analyze data, and compile the research report. Researcher fees typically account for the largest portion of the research budget due to the extensive time commitment and expertise required.

Interview Costs are the second-largest expenditure, totaling $4,500. These costs are calculated based on payments to 150 participants, each receiving $30 per interview as a form of incentive or compensation for their time and effort. Participant incentives are critical to ensuring participation, particularly in qualitative research where the involvement of experienced healthcare professionals is required.

Transcription Services amount to $1,500, calculated for 30 hours of recorded interviews and FGDs at a rate of $50 per hour. This cost is essential for converting audio data into written text, which is necessary for thematic analysis and report preparation. Since transcription is labor-intensive and requires high accuracy, it is often outsourced or managed by specialized personnel.

The cost for Data Analysis Software is $1,000. This cost reflects the purchase of a software license to support thematic analysis and qualitative data management. Such software provides tools for coding, categorization, and thematic analysis of interview and FGD transcripts.

Administrative Costs are listed as $1,000. These cover miscellaneous expenses, such as logistics, printing, communication, and supplies needed to support the smooth implementation of research activities. Although administrative costs are the smallest budget item, they are necessary to cover the indirect costs of research operations.

The total cost for the research amounts to $20,000, ensuring that all required resources are available to complete the study efficiently and effectively.

Analysis of the Figure

The Figure visually illustrates the distribution of total costs for each cost item, with the x-axis representing the five cost items and the y-axis indicating the total cost in U.S. dollars (USD). The changes in the slope of the graph highlight the relative differences in expenditure across the various cost components.

The first point on the graph represents Researcher Fees, which is the highest expenditure at $12,000. This steep rise in the graph signifies the large share of the budget allocated to human resources. Researcher fees are essential because they cover the wages of skilled professionals who facilitate data collection, conduct thematic analysis, and manage overall project execution. The steep increase highlights the high relative cost of this activity compared to the other cost items.

The graph then shows a sharp decline to the next point, representing Interview Costs at $4,500. The drop from Researcher Fees to Interview Costs reflects a significant reduction in expenditure, although Interview Costs remain

the second-largest budget item. The cost of participant incentives is a critical component of the budget, as it supports participant recruitment and encourages participation in the study. The downward shift on the graph illustrates that, while important, Interview Costs are significantly lower than Researcher Fees.

Following this, the graph further declines to Transcription Services, which cost $1,500. This decline signifies a reduction in financial allocation compared to previous activities. Transcription is necessary to convert interview and focus group recordings into written format for analysis, but it requires less financial commitment relative to human resources and participant incentives. The gradual slope of the graph from Interview Costs to Transcription Services reflects the decreasing share of the budget required for this cost item.

The graph continues to decline to the cost of Data Analysis Software, which is $1,000. This expenditure reflects the purchase of a single license for specialized qualitative analysis software. The line graph shows a marginal decrease from Transcription Services to Data Analysis Software, as these two components require relatively similar levels of financial input.

The final point on the graph represents Administrative Costs, which total $1,000. This cost item is at the same level as Data Analysis Software, indicating that both activities require an equal share of the budget. Administrative Costs cover logistics, printing, and other operational expenses that support the successful implementation of the research project. The flat slope between Data Analysis Software and Administrative Costs highlights their equal cost allocation.

The table and graph reveal that the largest share of the budget is dedicated to Researcher Fees, which accounts for 60% of the total budget. This allocation underscores the importance of human resources in qualitative research, particularly for activities such as data collection, transcription review, and report writing. Interview Costs are the second-highest expenditure, reflecting the value placed on participant engagement and the importance of incentives to encourage participation. Other costs, such as Transcription Services, Data Analysis Software, and Administrative Costs, have relatively smaller allocations, but they remain essential for the smooth execution of the research process.

The Figure highlights the sharp rise from Administrative Costs to Researcher Fees, illustrating the disproportionate share of the budget required for personnel. The gradual slope across the other cost items illustrates the smaller and more evenly distributed nature of expenses for activities like transcription, software licensing, and administrative support. This clear and visual presentation of the budget allows for effective tracking and ensures that sufficient funds are allocated for each critical task. The structured distribution of costs ensures that the research process remains efficient, timely, and fully supported by the necessary resources.

5. Conclusion and Recommendations

5.1 Conclusion

In conclusion, this study has demonstrated the vital role of clinical laboratory services in enhancing pharmaceutical care through improved collaboration, evidence-based decision-making, and patient-centered treatment. By integrating laboratory data into the pharmaceutical care process, healthcare systems can achieve more accurate medication management, reduce adverse drug reactions, and promote personalized treatment approaches. The findings highlight that timely access to laboratory results enables pharmacists to make more informed drug-related decisions, thereby enhancing patient safety and therapeutic outcomes.

The integration of laboratory services with pharmaceutical care has been shown to foster effective interprofessional collaboration. By facilitating real-time data sharing and joint decision-making, laboratory services support a collaborative healthcare environment where pharmacists, physicians, nurses, and laboratory technologists work together toward shared goals. The establishment of standardized protocols and electronic health records (EHRs) has further strengthened this collaboration, allowing healthcare teams to communicate seamlessly and provide integrated care for patients.

Moreover, the findings emphasize the importance of therapeutic drug monitoring (TDM) as a key component of collaborative pharmaceutical care. Laboratory data plays a critical role in optimizing drug regimens for patients, especially for medications with narrow therapeutic indices. Through close coordination between laboratory technologists and pharmacists, drug dosages can be personalized, ensuring greater efficacy and minimizing toxicity. This process ultimately leads to improved patient outcomes and more effective healthcare delivery.

Despite the numerous benefits, certain challenges persist, such as role ambiguity, communication barriers, and limited access to laboratory data. Addressing these issues requires clearer role definitions, enhanced interprofessional education, and investment in technology to improve access to laboratory results. By overcoming these challenges, healthcare systems can strengthen collaboration between pharmacists and laboratory professionals, further enhancing pharmaceutical care.

clinical laboratory services play a fundamental role in modern healthcare systems by supporting evidence-based decision-making, promoting interprofessional collaboration, and enabling patient-centered treatment. The findings of this study underscore the need for healthcare institutions to adopt integrated models of care that leverage laboratory data for optimal therapeutic outcomes. Through continued innovation and collaborative practice, healthcare providers can ensure more effective and efficient pharmaceutical care, ultimately leading to safer and higher-quality patient care.

5.2 Recommendations

Based on the findings of this study, several key recommendations can be made to enhance the role of clinical laboratory services in pharmaceutical care. These recommendations aim to strengthen interprofessional collaboration, improve the use of laboratory data in therapeutic decision-making, and optimize patient outcomes. Addressing the challenges identified in the study will support the development of a more integrated and effective healthcare system where laboratory services are fully utilized to support pharmaceutical care.

First, healthcare institutions should establish clear guidelines and protocols that define the roles and responsibilities of clinical pharmacists, laboratory technologists, and other healthcare professionals involved in collaborative care. This clarity will reduce role ambiguity and improve coordination among team members. Standard operating procedures (SOPs) should be revised to promote joint accountability in decision-making processes related to drug therapy adjustments and patient care interventions.

Second, healthcare facilities should invest in technological solutions, such as electronic health record (EHR) systems, to facilitate the real-time sharing of laboratory data among pharmacists, physicians, and laboratory staff. Enhanced access to laboratory results will enable healthcare providers to make timely, evidence-based decisions, particularly for therapeutic drug monitoring (TDM) and personalized medicine initiatives.

Third, it is recommended that healthcare providers implement interprofessional education and training programs that focus on collaborative care models. Training sessions and workshops can help clinical pharmacists, laboratory technologists, and nurses build trust, enhance communication, and understand the shared goals of collaborative healthcare. These initiatives will strengthen teamwork and foster a culture of continuous learning.

Finally, healthcare systems should address barriers such as communication gaps, limited access to laboratory data, and operational inefficiencies. By addressing these barriers, healthcare institutions can ensure a more integrated approach to care delivery. Adopting these recommendations will create a more collaborative healthcare environment where laboratory services play a central role in enhancing pharmaceutical care, ultimately improving patient safety and clinical outcomes.

References

1. Abdulrhim, S. H., Saleh, R. A., Hussain, M. A. M., Al Raey, H., Babiker, A. H., Kheir, N., & Awaisu, A. J. V. i. h. r. i. (2019). Impact of a collaborative pharmaceutical care service among patients with diabetes in an ambulatory care setting in Qatar: amultiple time series study. *19*, 45-50 .
2. Abousheishaa, A. A., Sulaiman, A. H., Huri, H. Z., Zaini, S., Othman, N. A., bin Aladdin, Z., & Guan, N. C. (2020). *Global scope of hospital Pharmacy practice: A Scoping review.* Paper presented at the Healthcare.
3. Alhossan, A., & Alazba, A. J. S. P. J. (2019). Barriers interfering with establishment of Collaborative Drug Therapy Management (CDTM) agreements between clinical pharmacists and physicians. *27*(5), 713-716 .
4. Bergman, A. A., Jaynes, H. A., Gonzalvo, J. D., Hudmon, K. S., Frankel, R. M., Kobylinski, A. L., & Zillich, A. J. J. H. c. (2016). Pharmaceutical role expansion and developments in pharmacist-physician communication. *31*(2), 161-170 .
5. Bryant, R., Chaar, B., & Schneider, C. J. I. j. o. n. s. (2018). Differing clinical pharmacy service models: Quantitative and qualitative analysis of nurse perceptions of support from pharmacists. *86*, 90-98 .
6. Dodd, M. R. J. C. M. N. (2018). Prescription for Disruption: Including a Pharmacist as Part of the Clinical Laboratory Team. *40*(24), 199-204 .
7. Gordon, C., Unni, E., Montuoro, J., & Ogborn, D. B. J. I. J. o. P. P. (2018). Community pharmacist-led clinical services: physician's understanding, perceptions and readiness to collaborate in a Midwestern state in the United States. *26*(5), 407-413 .
8. Hallworth, M. T., Bayne, E., McKinnon, E., Love, O., Tremblay, J. A., Drolet, B., . . . Marra, P. P. J. P. o. t. R. S. B. (2021). Habitat loss on the breeding grounds is a major contributor to population declines in a long-distancemigratory songbird. *288*(1949), 20203164 .
9. Hallworth, M. T., & Marra, P. P. J. S. r. (2015). Miniaturized GPS tags identify non-breeding territories of a small breeding migratory songbird. *5*(1), 11069 .

10. Helgesen, A. K., Nome, C. M., Stenbjerg, J. K., Arnesen, M. H., Aardalen, T. R., Dilles, T., & Grøndahl, V. A. (2024). *Pharmaceutical Care in Primary Healthcare—A Study of Nurses', Pharmacists', and Physicians' Experiences of Interprofessional Collaboration.* Paper presented at the Healthcare.
11. Helgesen, E .H., Ulevåg, R., Solheim, T. S., Thronæs, M., Jakobsen, G., Løhre, E. T., . . . Vagnildhaug, O. M. J. C. O. (2024). Appetite Loss in Patients with Advanced Cancer Treated at an Acute Palliative Care Unit. *31*(10), 6061-6072 .
12. Kaboli, P. J., Hoth, A. B., McClimon, B. J., & Schnipper, J. L. J. A. o. i. m. (2006). Clinical pharmacists and inpatient medical care: a systematic review. *166*(9), 955-964 .
13. Kelly, D. V., Bishop, L., Young, S., Hawboldt, J., Phillips, L., & Keough, T. M. J. C. P. J. R. d. P. d. C. (20 .(13Pharmacist and physician views on collaborative practice: Findings from the community pharmaceutical care project. *146*(4), 218-226 .
14. Leguelinel-Blache, G., Castelli, C., Roux-Marson, C., Bouvet, S., Andrieu, S., Cestac, P., . . . Mouchoux, C. J. T .(2018) .Impact of collaborative pharmaceutical care on in-patients' medication safety: study protocol for a stepped wedge cluster randomized trial (MEDREV study). *19*, 1-8 .
15. Olver, P., Bohn, M. K., Adeli, K. J. C. C., & Medicine, L. (2023). Central role oflaboratory medicine in public health and patient care. *61*(4), 666-673 .
16. Pawłowska, J., Łącka, M., Kucharska, M., Pawlowski, J., & Zajączkowski, M. J. C. o. t. P. (2020). Multiproxy evidence of the Neoglacial expansion of Atlantic Water to eastern Svalbard .501-487 ,(2)16 .
17. Pawłowska, J., Wollenburg, J. E., Zajączkowski, M., & Pawlowski, J. J. S. R. (2020). Planktonic foraminifera genomic variations reflect paleoceanographic changes in the Arctic: evidence from sedimentary ancient DNA. *10*(1), 15102 .
18. Pharmacy, A. C. o. C., McBane, S. E., Dopp, A. L., Abe, A., Benavides, S., Chester, E. A., . . . Therapy, D. (2015). Collaborative drug therapy management and comprehensive medication management—2015. *35*(4), e39-e50 .
19. Sterling, J. J. H. P. (2010). Pharmacy andLaboratory Collaboration. In (Vol. 45, pp. 276-280): SAGE Publications Sage CA: Los Angeles, CA.
20. Watson, I. D., Wilkie, P., Hannan, A., Beastall, G. H. J. C. C., & Medicine, L. (2018). Role of laboratory medicine in collaborative healthcare. *57*(1), 134-1 .42
21. Yodoshi, M., Iwasaki, N., Satoh, K., Nomura, M., Morishima, Y., Nakae, K., & Yamazoe, Y. J. R. b. T. J. J. o. C. P. (2013). TDM management system for contribution to proper use of anti-mRSA drugs--establishment of cooperation support system between pharmacy and clinical laboratory in hospital. *61*(2), 127-134 .
22. Zargarzadeh, A. H., Jacob, S., Klotz, R. S., & Khasawneh, F. T. (2011). Clinical pharmacists and basic scientists: do patients and physicians need this collaboration? In: Springer.
23. Zerbino, D .R., Achuthan, P., Akanni, W., Amode, M. R., Barrell, D., Bhai, J., . . . Girón, C. G. J. N. a. r. (2018). Ensembl 2018. *46*(D1), D754-D761 .